For example, NSCLC patients without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR−/ALK−) seem to benefit from immunotherapy, while the response to immunotherapy seems to be poor in those who harbor EGFR-sensitive mutations and ALK rearrangements (EGFR+/ALK+) (7). This evidence concerns the gene ALK and non-small cell lung carcinoma.